Guideline Statement for the Treatment of Disseminated Intravascular Coagulation



Similar documents
Guideline Statement for Safe Medication Practices in the Perioperative Area

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

DVT/PE Management with Rivaroxaban (Xarelto)

Session Number 405 CERTIFICATION REVIEW: HEMATOLOGY AND IMMUNOLOGY

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

Sepsis: Identification and Treatment

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

ELSO GUIDELINES FOR TRAINING AND CONTINUING EDUCATION OF ECMO SPECIALISTS

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

Recommended Standards of Practice for Patient Transportation

Medical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, th Annual Great Lakes Cancer Nursing Conference Troy, MI

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

Heparin Induced Thrombocytopenia

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Blood Transfusion. There are three types of blood cells: Red blood cells. White blood cells. Platelets.

Recommendations: Other Supportive Therapy of Severe Sepsis*

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Standards of Practice for Patient Identification, Correct Surgery Site and Correct Surgical Procedure

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

Quality Scorecard overall heart attack care overall heart failure overall pneumonia care overall surgical infection rate patient safety survival

Sepsis Awareness Month

»medical programs and services. transfusion medicine fellowship program

School-age child 5-1 THE BLOOD

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

Dabigatran (Pradaxa) Guidelines

Platelet Review July Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

PSA Screening for Prostate Cancer Information for Care Providers

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

Clinical Guideline N/A. November 2013

If your doctor has ordered laboratory tests, it s natural

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

V: Infusion Therapy. Alberta Licensed Practical Nurses Competency Profile 217

Approved: Acute Stroke Ready Hospital Advanced Certification Program

NUR PATHOPHYSIOLOGY (3crs. Hrs.)

Master of Physician Assistant Studies Course Descriptions for Year I

2006 Provider Coding/Billing Information.

Description of the OECD Health Care Quality Indicators as well as indicator-specific information

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

»medical programs and services. transfusion medicine fellowship program

Preoperative Laboratory and Diagnostic Studies

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

APPENDIX B SAMPLE PEDIATRIC CRITICAL CARE NURSE PRACTITIONER GOALS AND OBJECTIVES

TRANSFUSION MEDICINE

Consent for Treatment/Procedure Laparoscopic Sleeve Gastrectomy

Blood products and pharmaceutical emergencies

Blood Transfusion. Red Blood Cells White Blood Cells Platelets

Overall Goals/Objectives - Surgical Critical Care Residency Program The goal of the Pediatric Surgical Critical Care Residency program is to provide

DRG 416 Septicemia. ICD-9-CM Coding Guidelines

How To Know If You Have A Bleeding Disorder

We have made the following changes to the Critical Illness events covered under our group critical illness policy.

A Career in Pediatric Hematology-Oncology? Think About It...

Emerging therapies for Intracerebral Hemorrhage

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

How To Become A Nurse Practitioner

Children's Medical Services (CMS) Regional Perinatal Intensive Care Center (RPICC) Neonatal Extracorporeal Life Support (ECLS) Centers Questionnaire

Introduction Hemophilia is a rare bleeding disorder in which the blood does not clot normally. About 1 in 10,000 people are born with hemophilia.

Informed Consent for Laparoscopic Vertical Sleeve Gastrectomy. Patient Name

New Oral Anticoagulants

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Level III Stroke Center Data Collection Requirements

SAMPLE. UK Obstetric Surveillance System. Management of Pregnancy following Laparoscopic Adjustable Gastric Band Surgery.

Plumbing 101:! TXA and EMS! Jay H. Reich, MD FACEP! EMS Medical Director! City of Kansas City, Missouri/Kansas City Fire Department!

Adult Health Nursing

GASTRIC BYPASS SURGERY CONSENT FORM

Bakersfield College Associate Degree Nursing NURS B28 - Medical Surgical Nursing 4

INFORMED CONSENT - CARPAL TUNNEL RELEASE

Critical Bleeding Reversal Protocol

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES

ELSO GUIDELINES FOR ECMO CENTERS

Advanced Heart Failure & Transplantation Fellowship Program

Damage Control in Abdominal Trauma

PATIENT CONSENT TO PROCEDURE - ROUX-EN-Y GASTRIC BYPASS

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS

Selective IgA deficiency (slgad)

Certified Clinical Documentation Specialist Examination Content Outline

Admission to the Second Degree BSCLS Program. Prerequisite Course Requirements for Second Degree BSCLS

A: Nursing Knowledge. Alberta Licensed Practical Nurses Competency Profile 1

Acute Myeloid Leukemia

Welcome to the Austin Community College s online Medical Laboratory Technician Program Information Session.

ACUTE MYELOID LEUKEMIA (AML),

Thibodeau: Anatomy and Physiology, 5/e. Chapter 17: Blood

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

Stem Cell Quick Guide: Stem Cell Basics

Acute myeloid leukemia (AML)

Phlebotomy Handbook Blood Collection Essentials Seventh Edition

Extracorporeal Life Support Organization (ELSO) Guidelines for Neonatal Respiratory Failure

Transcription:

Guideline Statement for the Treatment of Disseminated Intravascular Coagulation Introduction Though a rare occurrence in the perioperative setting, disseminated intravascular coagulation (DIC) is a syndrome that the CST and CFA should understand and be prepared to assist in treating. AST developed the following guideline statement to provide support to health care facilities to aid in the reinforcement of the recognition of DIC and methods of treatment in the perioperative setting. The purpose of this Guideline Statement is to provide information that health care providers in the perioperative setting can use to develop and implement policies and procedures for the treatment of DIC. The guideline is presented with the understanding that it is the responsibility of the health care facilities to develop, approve and establish policies and procedures for treating DIC according to established hospital protocols, state and federal medical laws. AST Guideline Statement The Certified Surgical Technologist (CST) and Certified First Assistant (CFA) are qualified to assist in the methods used to treat DIC and its underlying causes in the surgical setting under the direct supervision of the surgeon Pathology DIC is a complicated systemic disorder of the body s hemostatic process that involves a combination of hemorrhaging and microvascular coagulation. It is most often referred to in terms of being a hemorrhagic disorder, due to the difficulties associated with bleeding; however, the complications that occur with the microvascular clotting must be also be recognized as being associated with true DIC. 11 DIC is a repeating cycle of clot formation and fibrinolysis of the clot, leading to the depletion of platelets and coagulation factors, including the constant release of anticoagulants. As the level of the platelets decreases, systemic microvascular coagulation occurs in the bloodstream and within the organs of the body. At the same time, the depletion of the platelets and coagulation proteins results in the inducement of severe bleeding. DIC can range from low-grade with minimal symptoms and complications to fulminate DIC that presents with life-threatening bleeding and coagulation abnormalities. 11 Causes DIC is an acquired disorder that occurs in a variety of clinical conditions. The common causes are listed in Table 1. Infectious disease, particularly septicemia, is the most common clinical condition associated with DIC. 6 Most microorganisms can cause DIC, but bacterial infection is most frequent. Contrary to popular belief and information, DIC seems to occur as often in patients with gram-positive sepsis as in those with gram-

negative sepsis. 6 Approximately 10%-20% of patients with gram-negative bacteremia display evidence of DIC. 1 Another clinical occurrence commonly associated with the development of DIC is severe trauma, in particular, trauma to the brain tissue. A combination of factors contributes to triggering DIC, including the release of fat and phospholipids from tissue into the circulation, hemolysis, and endothelial damage. 6 DIC is a common complication associated with abruptio placentae and amnioticfluid embolism, occurring in more than 50% of patients who experience these obstetrical conditions. 6 These conditions may cause fulminant DIC, but the DIC tends to be a shortterm condition, once the underlying disorder has been treated. Table 1: Common Clinical Conditions Associated with the Cause of DIC Trauma Brain tissue injury Fat embolism Massive transfusion Cancer Leukemia Solid tumors Obstetrical Complications Retained fetus Abruptio placentae Amniotic fluid embolism Immunologic Syndromes Hemolytic transfusion reaction Anaphylactic reaction Transplant rejection Vascular Conditions Aortic aneurysm Giant hemangioma Gram-positive or gram-negative sepsis Diagnosis There is no single laboratory test establishing the definitive standard for diagnosing or ruling out DIC. A combination of tests is performed when a patient presents with a clinical condition known to be a triggering factor. DIC can be diagnosed based on the following 6 : Recognition of underlying condition associated with DIC Platelet count of less then 100,000 per cubic millimeter or the platelet count rapidly decreases. Prolonged prothrombin time Prolonged activated partial-thromboplastin time Presence of fibrin-degradation products in plasma Low plasma levels of coagulation inhibitors, such as antithrombin III

Physical signs 1 : Spontaneous bruising Petechiae GI bleeding Perfuse bleeding at surgical wound site Intracranial bleeding Respiratory tract bleeding Treatment and Prognosis The number one management protocol of DIC is treating the underlying disorder or condition, such as sepsis, abruptio placentae, hemolytic transfusion reaction, etc. By not treating the underlying cause, treatment of DIC will fail. However, treatment modalities will differ according to the presenting symptoms of the patient. For example, a patient who presents with severe hemorrhaging will require supportive treatment that will differ from the patient that presents with microvascular coagulation that can lead to multi-organ failure. The following presents further information as related to the therapeutic management of DIC. The administration of heparin therapy has been widely debated and remains controversial. Informal studies have been conducted of patients with DIC, but no formal clinical trials have been completed. Available information has not proven that heparin increases the chances of bleeding complications and while some patients benefit from its use, it should be carefully used and administered in low doses. If given, heparin is administered through continuous IV infusion at 300-500 units per hour. 6 Patients with DIC exhibiting a decreased level of platelet and coagulation factors can be at risk for serious bleeding, when undergoing an invasive surgical procedure. These patients will obviously benefit from infusion of platelet concentrate and plasma. Additionally, these patients will benefit from the administration of vitamin K since they will exhibit a deficiency in the vitamin. 1 Treatment with coagulation-factor concentrates is contraindicated due to the concentrates possibly being contaminated with activated coagulation factors. Concentrates only contain certain coagulation factors, and the patient with DIC is deficient in all coagulation factors. 6 Antithrombin III may be considered for use as part of the overall treatment of the patient with DIC. Antithrombin III is one of the body s natural inhibitors of coagulation and studies have shown its effectiveness. 6 However, its cost prohibits widespread use. The mortality and morbidity rates of fulminate DIC remain high and are related to the severity of the underlying disorder. The more intense the bleeding, the higher is the risk of patient death occurring. Additionally, studies have shown that the development of DIC in patients with severe sepsis or trauma approximately doubles the risk of death. 6 Competency Statements Competency Statements 1. The CST and CFA can assist in the treatment of a patient with DIC under the direct supervision of the surgeon. Measurable Criteria 1. Educational standards as established by the Core Curriculum for Surgical Assisting and the Core Curriculum for Surgical Technology. 2, 3

2. The CST and CFA can serve as runners to deliver blood samples to the lab, blood and blood-products from the blood bank for delivery to the O.R., and communicate blood sample lab results to the O.R. 3. Under the direct supervision of the surgeon, surgical assistants are qualified to appropriately interpret the results of the lab tests and communicate them to the O.R. team. 4. CSTs and CFAs are qualified to locate and set up the blood-warming unit. 5. CSTs and CFAs can assist in the documentation, such as the clinical record and patient s chart. 2. The subject area of transfusion, blood, and blood-products is included in the didactic studies as a student. 3. The treatment protocols for emergency situations, such as DIC, are included in the didactic studies as a student. 4. Students demonstrate knowledge of the transfusion equipment, such as the bloodwarming unit through didactic studies. 5. As practitioners, CSTs and CFAs perform patient care duties by assisting the surgeon and surgical team, when a patient is experiencing DIC. 6. Advanced knowledge of transfusion, assessment of normal and abnormal fluid balance, and other IV replacement therapies, including interpretation of lab results are included in the didactic studies of surgical assistant students. 7. Surgical assistant students demonstrate advanced knowledge of transfusion of the surgical patient, assessing the fluid levels of the patient, and interpretation of lab results under the direct supervision of the surgeon during clinical rotation. 8. CSTs and CFAs complete continuing education to remain current in their knowledge of hemorrhage, transfusion of the surgical patient, and patient care duties as related to transfusion and DIC, including following the policies of the health care facility in completing annual in-service requirements. References 1. Baglin T. Fortnightly review: Disseminated intravascular coagulation: diagnosis and treatment. British Medical Journal. 1996; 312: 683-686.

2. Core Curriculum for Surgical Assisting. 2 nd ed. Littleton, CO: Association of Surgical Technologists; 2006. 3. Core Curriculum for Surgical Technology. 5 th ed. Littleton, CO: Association of Surgical Technologists; 2002. 4. Gaspard, KJ. Alterations in hemostasis and blood coagulation. In: Porth CM, ed. Essentials of Pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2004: 205-215. 5. Hennessy C, Porth CM. Heart failure and circulatory shock. In: Porth CM, ed. Essentials of Pathophysiology. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 320-338. 6. Levi M, Cate HT. Disseminated intravascular coagulation. N Engl J Med; 1999; 341(8): 586-592. 7. Morgan GE, Mikhail MS, Murray MJ, eds. Clinical Anesthesiology. 4 th ed. New York, NY: McGraw-Hill; 2006: 773-788. 8. Neighbors M, Tannehill-Jones R. Human Diseases. Albany, NY: Delmar Thomson; 2000. 9. Oberman HA. Complications of blood transfusion. In: Greenfield LJ, ed. Complications in surgery and trauma. 2 nd ed. Philadelphia, PA: JB Lippincott; 1990: 183-192 10. Phillips N. Berry & Kohn s Operating Room Technique. 10 th ed. St Louis, MO; Mosby; 2004. 11. Rutherford E J, Skeete D, Schooler WG, Fakhry, SM. Hematologic principles in surgery. In: Townsend CM, Beauchamp RD, Evers, BM, Mattox KL, eds. Sabiston Textbook of Surgery. 17 th ed. Philadelphia, PA: Elsevier; 2004: 113-136. 12. Silver D. Complications of coagulation and splenectomy. In: Greenfield LJ, ed. Complications in Surgery and Trauma. 2 nd ed. Philadelphia, PA: JB. Lippincott; 1990: 193-202. 13. Sugerman HJ. Complications of septic shock. In: Greenfield LJ, ed. Complications in Surgery and Trauma. 2 nd ed. Philadelphia, PA: JB Lippincott; 1990: 169-182.